Company
Adenocyte
A dramatically improved sample for dysplasia and cancer screening.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
A brief, extracorporeal application of a specially designed, FDA cleared, low intensity, non-focused ultrasound (“LINFU®”) beam, can significantly increase the natural rate of epithelial cell exfoliation into a surrounding body fluid – enhancing cytological specimens used to screen for dysplasia and cancer.
Funding snapshot
- Total raised
- $10MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Undisclosed, $10M
Funding rounds
- Round
- $10MCompany stated
Products
- Hardware
- LINFU®
Loading relationship preview